Intercellular telomere transfer research program
exploratoryresearch program · high · Thu Aug 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Understand and exploit telomere transfer at the immune synapse to rescue T cells from senescence and promote long-term immune memory or anti-ageing interventions.
Study of telomere vesicle transfer from antigen-presenting cells to T cells at the immunological synapse, including detection methods and mechanistic characterization.
2022 Nature Cell Biology publication and Sentcell site update reporting discovery of intercellular telomere transfer that rescues T cells from senescence.
Reported that telomere vesicles transferred from antigen-presenting cells elongate T-cell telomeres independently of telomerase and protect antigen-specific T cells from senescence.
COS
undiscloseddrug program · low
Pipeline program associated with Sentcell's sMAC therapeutic pipeline.
Undisclosed Sentcell pipeline candidate.
Listed in Sentcell's public pipeline.
Disruptors of the Sestrin-MAPK immune-inhibitory Complex
preclinicalplatform · high
Rejuvenate senescent T cells, increase T-cell fitness, generate long-lived stem-like memory features, and support immune protection in ageing-related contexts including vaccination and long-term T-cell conditions such as HIV.
Compounds that disrupt sestrin-MAPK immune-inhibitory complexes and drive sMAC degradation with downstream T-cell rejuvenation effects.
2024 bioRxiv publication describing first-in-class DOS compounds and preclinical effects in senescent T cells and old mice.
Reported increased T-cell fitness, stem-like memory features, new antigen-specific TCR rearrangements, and immune-protective responses to new challenges in old mice.
DOS144D
undiscloseddrug program · medium
Pipeline program associated with Sentcell's sMAC/T-cell rejuvenation therapeutic focus.
Undisclosed DOS pipeline candidate listed by Sentcell.
Listed in Sentcell's public pipeline.
DOS46L rejuvenating program
preclinicaldrug program · high
First-in-human rejuvenating therapy program targeting the sMAC pathway in ageing T cells.
Defined NCE/sMAC-pathway drug program; described as part of Sentcell's Disruptors of the Sestrin-MAPK immune-inhibitory Complex approach.
Series A funding in 2021 to support IMPD application for first-in-human DOS46L rejuvenating program and sMAC pipeline expansion.
Intracellular immunity functional HIV cure research program
exploratoryresearch program · medium
Restore patient-derived CD4+ T-cell capacity to eliminate HIV-infected reservoirs and support a functional HIV cure.
Transient ex vivo or in vivo reprogramming of CD4+ T cells using a defined compound or physiological induction to activate an antiviral telomere-transfer program.
2026 bioRxiv report describing clearance of HIV DNA in patient-derived cells and humanised mouse models.
Reported elimination of HIV DNA across reservoirs in humanised mice, undetectable viral genomes for months, and modelling suggesting unlikely rebound within a human lifespan.
LOS
undiscloseddrug program · low
Pipeline program associated with Sentcell's sMAC therapeutic pipeline.
Undisclosed Sentcell pipeline candidate.
Listed in Sentcell's public pipeline.
Mobiliser Of sMAC
preclinicaldrug program · medium
Promote sMAC formation to stimulate lymphocyte expansion under selected conditions, with potential relevance to aggressive cancers and other life-threatening conditions.
Patent-pending molecules that promote sMAC formation.
Publicly described as patent-pending MOS molecules developed by Sentcell.
NOS rejuvenation-sustaining program
preclinicaldrug program · medium
Sustain rejuvenation results after DOS-mediated rejuvenation.
Sentcell-described NOS application that can be combined with DOS.
Publicly described as combinable with DOS to sustain rejuvenation results.
